India Pharma Outlook Team | Friday, 15 May 2026
Telangana’s life sciences ecosystem has reached a landmark $145 billion valuation, marking a major milestone in India’s pharmaceutical industry and biotechnology sectors. The achievement comes amid rising investments, policy support, and Hyderabad’s emergence as a global healthcare innovation hub.
Backed by over Rs 84,000 crore investments in the last two years, Telangana has strengthened its position as a preferred destination for pharmaceutical manufacturing, biotechnology, medical devices, and healthcare research. Officials said the state’s life sciences industry has nearly tripled in size since 2016, reflecting rapid expansion across multiple healthcare segments.
The milestone was highlighted during the seventh Board Meeting of the Telangana Life Sciences Foundation (TLSF), chaired by Industries and Commerce Minister D. Sridhar Babu. According to government officials, Hyderabad now hosts innovation and technology centers for nine of the world’s top ten life sciences companies, reinforcing Hyderabad life sciences hub as a leading destination for global healthcare and pharmaceutical development.
The state government credits this rapid growth to consistent industrial policies, world-class infrastructure, and increasing investor confidence. Hyderabad’s established pharmaceutical base, combined with rising biotech industry growth and healthcare technology innovation, has attracted both domestic and international firms looking to expand manufacturing and research capabilities.
Also Read: Bajaj Group's Rs 2,000 Crore Healthcare Bet Begins in Pune
As Telangana looks beyond conventional pharmaceutical manufacturing, the government is focusing on higher-value areas such as biologics, medical technology, digital healthcare, and advanced therapies. Officials believe this diversification will strengthen the state’s long-term competitiveness in the global healthcare sector.
The recently launched Next-Generation Life Sciences Policy 2026–30 aims to attract $25 billion investments and create more than five lakh jobs by the end of the decade. The policy also seeks to position Telangana among the world’s top five life sciences ecosystems, with a strong emphasis on innovation, sustainability, and global partnerships.
Minister D. Sridhar Babu said Telangana is entering a new growth phase with projects designed to scale manufacturing and accelerate research-led development. One of the major proposals under consideration is the Green Pharma City Telangana, expected to attract nearly Rs 20,000 crore investments while expanding pharmaceutical production capabilities.
Industry experts say Telangana’s rise highlights India’s growing role in global healthcare manufacturing and innovation. Hyderabad has already established itself as a major vaccine production hub, as well as an important center for active pharmaceutical ingredients (API) and contract drug manufacturing.
The government is also investing in talent development and strengthening research institutions to sustain future growth. Plans are underway to support emerging sectors such as AI in healthcare, gene therapy, and precision medicine.
As Telangana’s life sciences valuation reaches $145 billion, industry leaders see the milestone as more than a financial achievement. It signals the state’s growing influence in shaping the future of healthcare, biotechnology, and pharmaceutical innovation on a global scale.
.jpg)
.jpg)
